RNS Number : 0295B
Kromek Group PLC
28 September 2022

28 September 2022

Kromek Group plc
("Kromek" or the "Group")

Result of AGM

Kromek Group plc, a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, announces that at its Annual General Meeting ("AGM"), held earlier today, all resolutions were duly passed.

Details of the proxy voting results, which should be read alongside the Notice of AGM, are below:

Resolution	Votes for		Votes against		Votes withheld	Total proxy votes
	No. of votes	***% of votes cast****	***No. of votes***	***% of votes cast****	***No. of votes***	
1	112,220,646	86.39	17,681,118	13.61	1,078,673	130,980,437
2	115,291,082	99.86	165,766	0.14	15,523,589	130,980,437
3	129,721,238	99.87	165,766	0.13	1,093,433	130,980,437
4	129,738,814	99.88	159,648	0.12	1,081,975	130,980,437
5	129,762,701	99.89	142,089	0.11	1,075,647	130,980,437
6	129,502,126	99.80	260,622	0.20	1,217,689	130,980,437
7	128,972,926	98.59	1,841,399	1.41	166,112	130,980,437
8	122,754,043	93.74	8,196,966	6.26	29,428	130,980,437

*Excludes withheld votes

For further information, please contact:

Kromek Group plc
Arnab Basu, CEO +44 (0)1740 626 060
Paul Farquhar, CFO

finnCap Ltd (Nominated Adviser and Broker)
Geoff Nash/Seamus Fricker/George Dollemore - Corporate Finance +44 (0)20 7220 0500
Tim Redfern/Charlotte Sutcliffe - ECM

Gracechurch Group (Financial PR)
Harry Chathli, Claire Norbury +44 (0)20 4582 3500

About Kromek Group plc

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has

manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation technology, are primarily used to protect critical infrastructure and urban environments from the threat of 'dirty bombs'.

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.

Further information is available at www.kromek.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGEAFNPAALAEFA